Vertex grows on back of Trikafta/Kaftrio sales

8 February 2023
vertex_large

US biopharma Vertex Pharmaceuticals (Nasdaq: VRTX) has reported its fourth-quarter and full-year financial results.

Revenue for the quarter came in at $2.3 billion, exactly on the analyst consensus estimate and 11% up on the same period of 2021. For the full year, the figure was $8.93 billion, 18% more than the previous year.

Quarterly earnings per share were $3.15, up 5%, while for the full year, they rose 42% to $12.82.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology